In Vivo
International IP Arbitration - A Blessing or a Bad Idea?
October 2019
Summary
Medtech companies traditionally resolved disputes over IP rights before national courts, but more and more of them are now turning to international arbitration to protect their IP rights. Dorothee Schramm explains the benefits of this growing trend and the pitfalls to avoid.
Authors:
Dorothee Schramm
Contacts
Related Capabilities
SERVICES AND INDUSTRIES
- Global Arbitration, Trade and Advocacy
- Global Life Sciences
- EU - Food, Drug and Medical Device Regulatory
GLOBAL REACH
Offices
Stay Up To Date